NASDAQ : BCTX

BriaCell Therapeutics Corp. — Company profile

Healthcare · Biotechnology · Canada

Last price 3.03 USD (Oct 30, 2026, 2:35 PM EDT) · Market cap 26.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Details

NameBriaCell Therapeutics Corp.
SectorHealthcare
IndustryBiotechnology
Employees16
Founded2014
CeoWilliam Williams
CountryCanada
ExchangeNASDAQ
Fiscal YearAugust - July
Reporting CurrencyUSD
IsinCA1079303071
Cusip107930307
Cik1610820
Sic2834

Key executives

NameTitle
Dr. William V. Williams FCPA, M.D.Chief Executive Officer, President and Director
Gadi Levin B.Com., C.A., CPA, M.B.A.Chief Financial Officer and Corporate Secretary
Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer
Dr. Giuseppe Del Priore M.D., M.P.H.Chief Medical Officer
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor and Member of Scientific Advisory Board

Contact

AddressBellevue Centre, Suite 300, West Vancouver, BC V7T 2X1, Canada
Phone604 921 1810
Websitehttps://briacell.com